Maze Therapeutics (NASDAQ:MAZE) CMO Sells 9,705 Shares of Stock

Key Points

• Maze Therapeutics CMO Harold Bernstein sold 9,705 shares at an average price of $26.22, generating $254,465 in proceeds. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and follows several additional insider sales since July.
• Maze shares rose 0.6% to $26.37, but remain below their 50-day and 200-day moving averages. The company has a $1.46 billion market capitalization and reported a quarterly loss of $0.76 per share, in line with analyst expectations.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $66 average price target, despite ratings ranging from “Sell” to “Strong Buy.”

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 9,705 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $26.22, for a total value of $254,465.10. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total transaction of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Trading Up 0.6%

NASDAQ MAZE traded up $0.16 on Tuesday, reaching $26.37. The company had a trading volume of 365,002 shares, compared to its average volume of 636,081. The stock's 50 day moving average is $28.64 and its 200-day moving average is $30.92. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -10.46 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 52 week low of $14.75 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.76). Equities analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MAZE. BTIG Research reiterated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $66.00.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada grew its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the 4th quarter worth about $43,000. California State Teachers Retirement System lifted its position in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after buying an additional 766 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth about $48,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.